This requirement was added to existing legislation last year in an effort to counter the growing issue of counterfeit medicines — which has increased exponentially in recent years because of increasingly complex supply chains, the expansion of e-commerce and a lack of enforcement capacity.
Falsified medicines are an industry wide issue and are not only extremely dangerous to patients, but can also cause significant harm to the brands that manufacture legitimate products — as patients are likely to lose confidence in a brand if it is widely counterfeited.
It is essential that pharmaceutical companies respond expeditiously to ensure that their products are well protected and comply with the upcoming legislation.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.